Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118047 | 0.81 | ALDH1A1 (0.31) | ALDH1A1POLBKMT2A | |
| SCHEMBL11763540 | 0.73 | ALDH1A1 (0.32) | ALDH1A1POLBKMT2A | |
| SCHEMBL21530480 | 0.68 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL14560305 | 0.68 | HSD17B10 (0.38) | ALDH1A1KMT2A | |
| SCHEMBL2491769 | 0.68 | ALDH1A1 (0.36) | ALDH1A1POLBKMT2A | |
| SCHEMBL21531656 | 0.67 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL18190428 | 0.63 | ALDH1A1 (0.32) | ALDH1A1POLBKMT2A | |
| SCHEMBL18721951 | 0.60 | MEN1 (0.30) | ALDH1A1KMT2A | |
| SCHEMBL11761527 | 0.59 | SMN1; SMN2 (0.38) | ALDH1A1POLBKMT2A | |
| SCHEMBL2543556 | 0.57 | KDR (0.41) | ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | ALDH1A1 2044/4885POLB 3294/4885KMT2A 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.